Morton Brown Family Wealth LLC Takes Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Morton Brown Family Wealth LLC acquired a new position in Gilead Sciences, Inc. (NASDAQ:GILD) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 376 shares of the biopharmaceutical company’s stock, valued at approximately $35,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. FMR LLC lifted its holdings in Gilead Sciences by 79.4% in the third quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company’s stock valued at $2,780,329,000 after buying an additional 14,680,161 shares during the period. Wellington Management Group LLP increased its holdings in Gilead Sciences by 50.9% in the third quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company’s stock worth $2,900,921,000 after purchasing an additional 11,665,593 shares in the last quarter. Pacer Advisors Inc. lifted its stake in Gilead Sciences by 723.3% in the fourth quarter. Pacer Advisors Inc. now owns 6,434,665 shares of the biopharmaceutical company’s stock valued at $594,370,000 after buying an additional 5,653,075 shares during the period. Point72 Asset Management L.P. boosted its holdings in shares of Gilead Sciences by 350.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 2,305,270 shares of the biopharmaceutical company’s stock worth $193,274,000 after buying an additional 1,793,145 shares in the last quarter. Finally, International Assets Investment Management LLC increased its stake in shares of Gilead Sciences by 8,238.4% in the 3rd quarter. International Assets Investment Management LLC now owns 1,642,504 shares of the biopharmaceutical company’s stock valued at $137,708,000 after acquiring an additional 1,622,806 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have commented on GILD shares. Daiwa America upgraded shares of Gilead Sciences to a “hold” rating in a report on Monday, November 18th. UBS Group raised their price objective on Gilead Sciences from $70.00 to $96.00 and gave the company a “neutral” rating in a research note on Thursday, November 21st. Piper Sandler boosted their price target on shares of Gilead Sciences from $105.00 to $110.00 and gave the company an “overweight” rating in a research note on Wednesday, February 12th. Robert W. Baird boosted their target price on shares of Gilead Sciences from $80.00 to $95.00 and gave the stock a “neutral” rating in a research report on Thursday, November 7th. Finally, Morgan Stanley lifted their target price on Gilead Sciences from $113.00 to $123.00 and gave the company an “overweight” rating in a research report on Wednesday, February 12th. Eleven equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and four have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $101.33.

Insider Activity

In other Gilead Sciences news, Director Jeffrey Bluestone sold 6,788 shares of Gilead Sciences stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total value of $620,355.32. Following the transaction, the director now directly owns 8,920 shares of the company’s stock, valued at approximately $815,198.80. The trade was a 43.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Merdad Parsey sold 164,211 shares of the business’s stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total value of $15,094,275.12. Following the transaction, the insider now owns 80,801 shares in the company, valued at approximately $7,427,227.92. This trade represents a 67.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 710,500 shares of company stock worth $67,684,956. 0.16% of the stock is currently owned by company insiders.

Gilead Sciences Stock Performance

Shares of NASDAQ:GILD opened at $104.08 on Tuesday. The company has a market capitalization of $129.71 billion, a price-to-earnings ratio of 1,156.44, a PEG ratio of 1.25 and a beta of 0.18. The firm’s 50-day moving average is $93.87 and its 200 day moving average is $87.70. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $106.69. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. Research analysts predict that Gilead Sciences, Inc. will post 4.35 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be issued a dividend of $0.79 per share. The ex-dividend date is Friday, March 14th. This represents a $3.16 dividend on an annualized basis and a yield of 3.04%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s dividend payout ratio is currently 3,422.22%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.